Halmos Highlights Evaluation of the EGFR Inhibitor BDTX-1535 in NSCLC
Season 9, Episode 42, Nov 16, 2023, 07:45 PM
Dr Halmos discusses the ongoing investigation of the potent, selective, and irreversible EGFR inhibitor BDTX-1535 in patients with non–small cell lung cancer.